Understanding the Role of Oral Microbiota in Behçet's Disease (BEHCETBIOT)

Microbiota Clinical Trial

— BEHCETBIOT  

Official title:

Understanding the Role of the Salivary Microbiota and Microbiota Associated to Mucosa in Behçet's Disease

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04959435
• Other study ID #: RBHP 2021 ANDRE
• Secondary ID: 2021-A01648-33
• Status: Recruiting
• Start date: January 10, 2022
• Est. completion date: January 1, 2024

Study information

• Verified date: January 2022
• Source: University Hospital, Clermont-Ferrand
• Contact: Lise LACLAUTRE
• Phone: +33473754963
• Email: promo_interne_drci[@]chu-clermontferrand.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Behçet's disease (BD) is a systemic vasculitis that affects, especially, young people. Although its etiology remains unexplained, data suggest that the inflammatory response during BD results from a disruption of the homeostasis of innate and adaptive immune responses in genetically predisposed people. The microbiota could play a triggering role in BD, in particular the salivary and dental plaque microbiota. The aim of the Behçetbiot study is therefore to establish microbial profiles of dental plaque, pathological (on the mouth ulcer) and non-pathological mucous membrane, salivary and digestive and to compare them with control subjects not suffering from BD, related to the first degree, of the same socio-cultural level and to determine whether dysbiosis is correlated with a local and systemic pro-inflammatory response, by measuring salivary level of pro-inflammatory cytokines and blood level of CRP, fibrinogen, orosomucoïd and haptoglobin, and to compare them with controls.

Description:

All patients and their controls are sampled for stool, saliva, dantal plaque, oral mucosa, genital mucosa and blood during an annual follow-up visit or if they are hospitalised. Plaque, oral mucosa, genital mucosa salivary and blood will be collected during an annual follow-up visit. For stool samples, the collection material will be provided to the patient and they will be able to take the sample at home and bring it to the clinic, or send them via a carrier within 3 days. All the samples related to the study will be taken in the internal medicine in Clermont-Ferrand (France) or Pitie Salpêtrière, department of internal medecine, Paris,France or ophthalmology departments in Clermont-Ferrand. All sample will be stocked in biological center in Clermont-Ferrand before analyze. Microbiota analyzes will be realise at M2iSH laboratoty, inflammatory cytokines will be analyze in Clermont-Ferrand immunology laboratory, and pro-inflammatory parameters will be analyse in biochimy laboratory in Clermont-Ferrand.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: January 1, 2024
• Est. primary completion date: January 2023
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• Patients who meet the International criteria for the classification of Behçet's disease, revised in 2013)
• Patient who had developed the disease in the 5 years preceding the study.

Exclusion Criteria:

• Pregnant or breastfeeding women, or women who may be pregnant or breastfeeding.
• Subject placed under judicial protection.
• Patient had received antibiotic or probiotic or symbiotic therapy in the 6 weeks preceding inclusion

Related Conditions & MeSH terms

• Behçet Disease
• Behcet Syndrome
• Microbiota
• Oral Microbiota
• Physiopathology

Intervention

Other:
• biological samples collection
samples of blood, faeces, saliva, dental plaque, oral mucosa, genital mucosa

Locations

Country	Name	City	State
France	CHU de Clermont-Ferrand	Clermont-Ferrand

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Clermont-Ferrand

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Oral microbiota	Establish microbial profiles (quantitative and qualitative via analysis of bacterial DNA sequences encoding 16S rRNA) of dental plaque, pathological (on the aphta) and non-pathological oral mucosa and and salivary and compared them to control without Behçet's disease matched for sex, diet and socio-cultural level.	Day 0
Secondary	Intestinal microbiota	Establish microbial profiles (quantitative and qualitative via analysis of DNA sequences encoding 16S rRNA) of the intestinal microbiota by studying feces and comparing them to controls without Behçet's disease, of the same sex, diet and socio-cultural level	Day 0
Secondary	Short fatty acid	Determination of short-chain fatty acids (HPLC technique) in the stools of Behçet patients and compare them to control patients without Behçet's disease, of the same sex, diet and socio-cultural level	Day 0
Secondary	Pro-inflammatory cytokines	Determination of blood and saliva levels of IL-1beta, IL-6, IL-17, IL21, IL-23, Il-10, IFN gamma and TNF alpha (ELISA technique or multiplexed assay) and compare them to patients without Behçet disease, of the same sex, diet and socio-cultural level.; socio-cultural level	Day 0
Secondary	genital microbiota	Establish microbial profiles (quantitative and qualitative via analysis of DNA sequences encoding 16S rRNA) of the intestinal microbiota by studying feces and comparing them to controls without Behçet's disease, of the same sex, diet and socio-cultural level	Day 0